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Predicting chronic renal insufficiency in idiopathic membranous
glomerulonephritis
YORK PEI, DANIEL CATTRAN, and CELIA GREENWOOD
Department of Medicine, University of Toronto, Metro Toronto Glomerulonephritis Registry, and Clinical Epidemiology Unit, Samuel
Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
Predicting chronic renal insufficiency in idiopathic membranous gb-
merulonephritis. We developed an approach in quantifying the risk of
developing chronic renal insufficiency (CR1) based on a cohort of 184
patients with idiopathic membranous glomerulonephritis (IMGN), pro-
spectively followed by the Toronto Glomerulonephritis Registry be-
tween 1974 and 1988. After a mean follow-up period of 5.8 years, 26%
of patients developed CR1 (defined as persistent reduction of creatinine
clearance (Car) 60 mI/min/! .73 m2 for 12 months). We found that
when compared to the baseline probability of the unselected patients,
the severity of proteinuria at kidney biopsy added only marginally to the
prediction of CR1. We introduced a special test condition: persistent
proteinuria (PP) (that is, duration of proteinuria, g/day, above different
cut-off levels). We examined the positive predictive value (PPV) and
sensitivity (SEN) of 15 arbitrarily chosen levels of PP (that is, protein-
uria 4, 6 or 8 glday persisting for 9, 12, 18 or 24 months) to select
levels with optimal predictive characteristics. We found that PP  8
g/day for six months was a simple and useful predictor of CR1 with a
PPV and SEN of 66%. To further improve our prediction, we tested the
following parameters: age, sex, initial Sr and proteinuria, serum
albumin, hypertension, rate of change of Cr over time, and therapy
(steroids immunosuppressive drugs) in a multivariate analysis. Pro-
teinuria, initial C, and rate of change of C. were most important in
predicting CR1. Fifteen models were then developed by including each
patient's Cr at the start of PP and its rate of change during the time
period selected. Two models based on PP  4g/day for 18 months, or
6 g/day for 9 months significantly improved the PPV's for CR1 from
those based on the same levels of PP alone. Using these test conditions,
we can improve the prediction of CR1 from a baseline probability of
26% in unselected patients to a range of 55 to 86% in the "high-risk"
patients (with SEN > 60%). Application of these predictive strategies in
IMGN will be useful in managing the individual patients and in selecting
patients for clinical trials by limiting the exposure of potentially toxic
therapy to the "high-risk" patients.
Idiopathic membranous glomerulonephritis (IMGN) is a com-
mon form of primary glomerulopathy and an important cause of
chronic renal failure related to glomerular disease [1, 21. Its
natural course is quite variable: chronic or end-stage renal
failure will develop in 20 to 40% of patients [1, 3—111; yet
spontaneous complete remission also occurs in up to 35% of
patients [1, 4—li, 13, 14]. Despite several recent randomized
controlled trials in IMGN [12—14, 16], there remain major
controversies regarding its treatment with respect to therapeu-
tic effectiveness and acceptable toxicities [1, 15, 17—19]. An
ability to predict those at "high-risk" for developing chronic
renal failure would be useful since all the current treatments
carry a serious risk of toxicity [1, 2, 13—15, 19].
While several prognostic factors have been identified to be
associated with "poor" renal outcome, they remain qualitative
[1—11, 19]. Furthermore, most studies have examined these
"risk" factors at a single point in time and do not address the
changing and variable course of many patients with IMGN
[3—11]. Based on a prospective cohort of patients with IMGN
followed by the Toronto Glomerulonephritis Registry, we have
developed a quantitative approach in predicting the develop-
ment of chronic renal failure in this disease.
Methods
Patient selection and data collection
The organization and the clinical activities of the Toronto
Glomerulonephritis Registry have been previously detailed
[201. Since August 1974, five nephropathologists have for-
warded reports of all cases of biopsy-proven glomerulonephritis
to the registry. The initial clinical and laboratory data on these
patients at the time of renal biopsy and all their follow-up
information (prospectively collected at 2 to 6 month intervals)
are entered into a computer database. This database reflects a
regional experience of 18 community and university teaching
hospitals in Toronto, with a population of approximately 4.5
million.
Between August 1974 and August 1987, 272 cases of mem-
branous glomerislonephritis had been documented. Sixty-eight
cases were excluded because the follow-up period was less than
one year, or because of the finding of a potential secondary
cause on clinical review. In the remaining 204 patients, 20
patients presented with marked renal impairment (that is,
creatinine clearance (Ccr) <60 ml/min/1.73 m2) at the time or
within six months of their biopsy. Since our goal was to develop
an approach to predict the development of CR1, these patients
were excluded. Thus, 184 patients remaining were chosen as
the database for this study.
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For the purpose of this study, chronic renal insufficiency
(CR1) is defined as a creatinine clearance of less than 60
ml/minll .73 m2 persisting for at least 12 months. End-stage
renal failure (ESRF) is defined as patients who reached the
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Fig. 1. Defining the study parameters for
probability modeling. Each patient's data
were examined to determine if CR1 had
occurred during his/her course. Once the
patient was noted to have developed CR1,
only the data prior to CR1 were used for the
modeling (A). Persistent proteinuria PP(X,P Y) is defined as X g/day or more of
proteinuria persisting for at least Y months
during a patient's course. For example, the
patient in the upper panel had PP(8 g/day,
12 months) ( ), g/day,
18 months (— — — — — ) and
g/day for 24 months) (——)
during his course, whereas the patient in
panel B only had PP(6 glday, months)
( ) and PP(4 g/day,
months) (— — —). Symbols are:(_.__•_) C,4 () PRO.
stage where they required dialysis or renal transplantation. The
rate of change of Cr over time (SLP) is defined as the slope of
Ccr versus time in ml/min/1.73 m2 x (year). Nephrotic
syndrome is defined as proteinuria of 3.5 glday. Complete
remission is defined as proteinuria < 300 mg/day with stable or
improving Ccr. Hypertension is defined as sitting blood pres-
sure of greater than 140/95 mm Hg on two successive visits.
Development of predictive strategies for CR1
For each patient, we examined all the available data during
his/her course to decide whether or not CR! had occurred.
When a patient developed CR!, only data prior to the develop-
ment were used for our analysis (Fig. 1, upper panel). Since the
clinical and laboratory parameters of many patients with IMGN
often changed during their course, we felt that assessment of
risk based on one point in time was sub-optimal.
We made an assumption that within each patient the time
period when he/she had the worst level of sustained proteinuria
would be the most useful reference point for assessing his/her
CR! risk. We introduced a special variable, persistent protein-
uria (PP, defined as the duration of proteinuria, glday, above
different cut-off levels) and further determined its predictability
for CR1. Fifteen arbitrary levels of PP(X, Y) were chosen,
where X = proteinuria of 4, 6, or 8 g/day andY = 6, 9, 12, 18
or 24 months of its persistence. Their positive and negative
predictive values, sensitivity, specificity and accuracy for CR1
were then calculated (Appendix 1).
To further improve our prediction, we tested the following
variables in a multivariate analysis to select out predictors of
CR1: age, sex, initial serum creatinine (Sr) and quantita-
tive proteinuria, serum albumin, hypertension, slope of Cr
versus time (SLP), and treatment (steroids other immuno-
suppressive drugs). The best variables independently predicting
CR1 were proteinuria, Cr or Sr, and SLP. Steroid immu-
nosuppressive drugs did not influence either the incidence of
CR! or complete remission in our patient population. Fifteen
A
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At
presentation
At last
follow-up
Serum creatinine tM 93.5 30 167 88
Ccr mllmin/1.73 m2 93.2 25 74.5 88
Proteinuriag/day 6.5 4.3 4.1 4.9
Nephrotic syndrome % 72 39
Systolic BP mm Hg 135 21 136 18
Diastolic BP mm Hg 83 12 83 10
Chronic renal insufficiency % 0 26
Complete remission % 0 26
All data are expressed as mean SD or percent.
models were then developed by including each patient's C. at
the start of PP and its rates of change during the time period
selected (Appendix 2). To evaluate the performance of each
model in predicting CR!, its PPV and SEN were compared to
those based on the same level of PP alone.
Statistical methods
Descriptive data are expressed as mean SD or as percents.
Positive predictive value (PPV), negative predictive value
(NPV), sensitivity (SEN), specificity (SPEC) and accuracy
were generated using standard definitions (Appendix 1) [22].
Univariate and multivariate logistic regression analyses were
performed to test the clinical and laboratory predictors for CR!,
and to develop the 15 specific models. Regression analyses
were performed using BMDP and SAS statistical packages [21,
24].
Results
Outcomes of study patients
The mean age (± SD) of the 184 study patients at their kidney
biopsy was 43 17 years, and the male to female ratio was 2:1.
Their mean follow-up period (±sD) was 5.8 4 years. Our
patient characteristics at biopsy and at the last follow-up are
shown in Table 1. Over the observation period, 26% of our
patients developed CR! and another 26% developed a complete
remission. Fifteen of 47 patients with CR1 developed ESRF
during the study. None of the 47 patients with CR! had
recovered his/her Cr above 60 ml/min/1.73 m2 at the last
follow-up. Fifty percent of our study patients were treated with
a course of corticosteroids during their course, and 26 of them
also received another immunosuppressive drug (such as cyclo-
phosphamide or azathioprine).
Predicting CR1 by different levels of persistent proteinuria
(PP)
Proteinuria at a single point in time adds only marginally to
the prediction of CR!. For example, the PPV of our patients
with proteinuria  8 g/day at renal biopsy is only 42% as
compared to the baseline risk of 26% in the unselected patients.
Table 2 shows the test characteristics of different levels of PP in
predicting CR!. Here, the PPV for each level of PP is improved
when compared to the same level of proteinuria at a single time
point. At higher level of PP such as PP(6 glday, months) or
PP(8 g/day, 6 months), there is more than a doubling of the
PPV (for example, 54—66%) from that of the unselected pa-
tients. For each level of PP, there is no significant improvement
proteinuria (PP) in predicting CR!
PP ( X glday,
 Y months) a
PPV" SEN NPV
(Expressed as percent)
SPEC
(X = 4 at Bx)C(X = 4, Y = 6)(X = 4, Y = 9)(X = 4, Y = 12)(X = 4, Y = 18)(X = 4, Y = 24)
127
92
75
61
36
23
32
44
44
44
47
44
87 89
85 92
70 87
58 84
36 80
21 77
37
62
69
75
86
91
(X = 6, at Bx)C(X = 6, Y = 6)(X = 6, Y = 9)(X = 6, Y = 12)(X = 6, Y = 18)(X = 6, Y = 24)
80
65
47
42
25
11
38
54
55
55
56
46
66 84
75 90
55 85
50 83
30 79
Il 76
64
78
85
86
92
96
(X = 8 at Bx)C(X = 8, Y = 6)(X = 8, Y = 9)(X = 8, Y = 12)(X = 8, Y = 18)(X=8,Y=24)
55
47
33
25
14
4
42
66
64
62
64
50
49 87
66 88
45 83
30 79
24 78
4 75
77
88
91
92
96
99
Abbreviations are: PPV, positive predictive value; SEN, sensitivity;
NPV, negative predictive value; SPEC, specificity (definitions are in
Appendix 1).
a Number of patients satisfying the PP condition
b The PPV in unselected patients is 26% (that is baseline risk)
Test characteristics of proteinuria at a single time point (such as at
around renal biopsy)
of PPV by increasing the length of its persistence beyond six
months. PP(8 g/day, months) is the best single level of PP
predicting CR! with a PPV and SEN of 66%.
In contrast, a patient with severe proteinuria has a low
probability of progressing to CR! if the proteinuria is not
persistent. For example, a patient with proteinuria 8 glday
but lasting less than six months has only a 12% probability of
developing CR! (that is, NPV of 88%).
Probability modeling in predicting CR!
To further improve our prediction of CR1 from that based on
PP alone, a general model has been developed and is shown
below:
exp(Ko + K, x PP + K2 x SLP + K3 x Ccr)
1 + exp(Ko + K x PP + K2 x SLP + K3 x Car)
This model has incorporated two additional measures of renal
function: Cr is the creatinine clearance at the start of PP
expressed in ml/min/1.73 m2, and SLP (slope) is the rate of
change of Cr during PP expressed in mllmin X (1.73 m2Y' X
(year'. PP is a categoric variable, and a value of 1 is entered
if a patient satisfies the specific level of PP for the model;
otherwise, a value of 0 is entered. K1, K2, and K3 are coeffi-
cients for PP, SLP and Car, respectively, and K0 is a constant.
Using the above equation, 15 specific models were generated
based on the corresponding levels of PP examined above.
From each model, a R(CRI) score is generated for each
patient based on his/her PP. Cr and SLP. This score reflects
the risk of a patient within a numerical interval of 0 and 1, where
0 represents no risk, and 1 represents a very high risk of
Table 1. Patient characteristics (N = 184) Table 2. Test characteristics of different levels of persistent
R(CRI) =
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0 0.17 0.33 O.0 0.67 0.83 1.0
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Fig. 2. Frequency distribution of patients by their R(CRJ) scores using
the model based on PP(8 g/day for months). The distribution of
R(CRI) scores in patients with CR! (N = 47) is shown in panel A, and
in patients without CR! (N = 137), in panel B. The test characteristics
of specific R(CRI) cut-offs for each model can then be defined for the
prediction of CR!.
developing CR1. To generate the corresponding predictive test
characteristics for each R(CRI) score within a model, the
R(CRI) scores are plotted in a frequency distribution. Using the
model M(8 glday for months) as an example, the distribu-
tion of the R(CRI) scores in patients who have developed CR!
is shown in the upper panel of Figure 2. Likewise, the distri-
bution of R(CRI) scores in patients who have not developed
CR1 is shown in the lower panel. By selecting different cut-offs
of R(CRI)'s in each model, we can evaluate the predictive
characteristics of these cut-offs. When our patients are tabu-
lated by whether they have developed CR! and by whether they
have exceeded a certain R(CRI) cut-off, the test characteristics
of a specific cut-off can be derived (such as 0.25 vs. 0.5) [221.
We have examined different R(CRI) cut-offs from 0.05, 0.1,
0.2, 0.3 . . . to 0.8 for their test characteristics in the above
models. We selected the optimal models based on their high
PPV's and SEN's. Three best models chosen whose perfor-
mances are very similar are based on PP(4 g/day for l8
0.2 0.4
R(CRI)
Fig. 3. Useful models for predicting CR1 in patients with IMGN. Three
models for predicting CR1 based on different levels of PP and renal
functional parameters are chosen for their optimal PPV (A) and SEN
(B). Symbols are: (Lr) M (4 glday, m); (*) M glday, 9 m);() M (8 g/day, m). The performances of these models are very
similar with respect to their PPV and SEN at each R(CRI) cut-off, but
they are different with respect to the duration of observation required.
To achieve the same risk of CR! with lower levels of proteinuria, a
longer persistence is required (see text for details).
months), PP(6 glday for months) and g!day for
months) (Fig. 3). They are different only with respect to the
duration of observation required. Across all models, the R(CRI)
score of 0.2 to 0.3 results in a doubling of the PPV (that is,
55—65%) from baseline (that is, 26%). An R(CRI) score of 0.5
gives an optimal performance in both PPV and SEN in these
models. Conversely, an R(CRI) score of less than 0.2 in these
models predicts low-risk patients for CR! (that is, <5%, or NPV
> 95%). The accuracy of these models at R(CRI) scores of 0.2
to 0.7 ranges between 78 to 83%. The coefficients used in these
models for PP, SLP and C. are shown in Appendix 2.
Figure 4 shows the comparisons of the predictive character-
istics of each of the above models (point M) with its correspond-
ing level of PP (point P) and single time-point proteinuria at
biopsy (point B). At all levels, PPV's based on single time-point
proteinuria as a predictor are significantly inferior to using the
corresponding level of PP or model. The top panel shows a
major improvement of both PPV (from 47 to 76%) and SEN
A A
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Fig. 4. Assessing the contribution of probability modeling in predicting
CR1. The PPV and SEN for CR1 based on a specific level of persistent
proteinuria (PP) (point P) are compared to the full model (point M)
based on a R(CRI) score of 0.5. A shows a dramatic improvement in
both PPV and SEN by our model in patients with PP(4 glday,  18
months). B shows a modest improvement by our model in patients with
PP(6 g/day, months). C shows minimal improvement by our model
in patients with PP(8 g/day, months). Single time-point proteinuria
at biopsy (point B) of 4 glday (A), glday (B), and g/day (C) only
improves the PPV marginally from its baseline probability (that is, 26%).
(from 36 to 60%) by our model when compared to its corre-
sponding level of PP in patients with PP(4 g/day,  18
months). The middle panel shows a smaller improvement of
PPV (from 55 to 69%) and SEN (from 55 to 62%) by our model
over PP alone in patients with PP(6 g/day, 9 months). The
bottom panel shows that in patients with PP(8 g/day, 6
months), there was minimal improvement by our model over PP
in the PPV and a small decrease in SEN.
Once any of the persistent proteinuria test conditions are
satisfied, most of the patients who are destined to developed
CR1 would develop this outcome within one year (median and
75th percentile time to CR1 is l and 12 months, respectively;
range: 0 months to 5 years).
Comments
Idiopathic membranous glomerulonephritis is a disease with a
variable course. Its natural history indicates that 20 to 35% of
patients will eventually undergo a complete remission, and
another 20 to 40% of patients will develop chronic or endstage
renal failure, while the remaining patients will have persistent
proteinuria and stable renal function [1, 3—14]. Thus, at least
two-thirds of patients with IMGN will have a generally benign
renal course, and treatment with potentially toxic drugs would
be best avoided in these patients U, 19].
Several factors have been suggested to identify the "high-
risk" patients for developing renal insufficiency in IMGN,
including: male sex, old age, proteinuria, impaired renal func-
tion, and hypertension at presentation [1—4, 7—11, 19]. How-
ever, all these prognostic factors are qualitative and their
application in a clinical setting remains uncertain. In this study,
we present a quantitative approach in predicting the develop-
ment of CR1 in patients with IMGN. Multivariate analysis in
our study showed that proteinuria, Car, and its rate of change
with time were the most important predictors.
We found that the severity of proteinuria at a single time-
point is not very useful in predicting CR1. We made an
assumption that within each patient the period when he/she has
the most severe level of sustained proteinuria would be an
optimal time for assessing this risk. The parameter, persistent
proteinuria (PP), became the basis for our risk quantitation.
Thus, PP(8 glday, months) is the single best level for
predicting CR1 with a PPV and SEN of 66%. Conversely, a high
NPV of 88% in the same test condition means that even severe
proteinuria of 8 g/day or more does not necessarily carry an
adverse prognosis provided that it is not persistent for over six
months. This reflects the fact that even patients with severe
proteinuria do undergo spontaneous complete remission in
IMGN [1, 3—14].
We propose the following approach for risk assessment: At
anytime during a patient's course if persistent proteinuria 8
g/day for six months is observed, that patient is in a "high-risk"
category with a 66% probability for developing CR!. Additional
and more complex modeling would not change this categoriza-
tion. If the patient has never exceeded this level of PP, the next
lower level (that is, proteinuria  6 g/day for 9 months or more)
should be checked. If this criterion is satisfied, then he/she has
a 55% probability of developing CR!. This may be a sufficient
threshold for treatment depending on the individual clinician.
However, if a higher threshold is desired before treatment is
indicated, then a more accurate prediction of CR1 can be
obtained by calculating the R(CRI) score using the model based
on PP(6 glday, m). If a patient has neither of the above
levels of PP, then PP(4 g/day, months) should be checked
1.0
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to see if the model based on this specific test criterion can be
used to improve the prediction.
When a patient does not meet any of the above levels of PP,
then any of the above models can be used to calculate a R(CRI)
score by setting PP = 0, and calculating the SLP based on the
interval of the worst proteinuria during the patient's course.
Using this serial test strategy, we can achieve a sensitivity of
greater than 80% and positive predictive value of about 70% for
predicting CR1.
To use any of the models, one needs to calculate the rate of
change of Cr over the chosen time period (SLP), and select the
appropriate formula and coefficients from Appendix 2. The
R(CRI) score can then be calculated by inserting the values of
PP. SLP and and its corresponding PPV and SEN can be
obtained from Figure 3. With this information, the clinician can
then decide on whether a patient has fulfilled his/her threshold
of being "high-risk" for a given treatment. For example, a
R(CRI) score of 0.5 in any of the three chosen models repre-
sents a risk of developing CR1 of greater than 70%.
A second application of these quantitative strategies would
be for selecting "high-risk" patients for a clinical trial. For
example, using any of the above three models we can select a
group of patients with greater than 60% probability for devel-
oping CR1. Since the sensitivity of this serial test strategy is
greater than 80%, the majority of patients who would develop
CR1 would be identified. The effect of selecting a "high-risk"
group for CR1 on the sample size required for a clinical trial can
be dramatic. For example, a potentially toxic new therapy in
IMGN is being tested using a randomized, placebo-controlled
design. Assuming that the CR1 event rate in the unselected
patients is 26%, and the effect of this therapy is clinically
significant if it reduces CR1 rate by 50% (that is, absolute CR!
rate of 13% in the treatment group). Using an a = 0.05 (2-tailed)
and /3 = 0.2, the sample size required in such a trial is 288
patients [23]. However, if the CR1 rate in another control group
with "high-risk" patients is 60%, and all other conditions are
the same, the sample size required for such a trial is only 84.
Thus, the number of patients exposed to the treatment arm is
only 42 in the trial with the "high-risk" patients in contrast to
144 in the trial with unselected patients. The conclusions of
both studies would be equally valid, but the number of patients
exposed to this potentially toxic treatment would be substan-
tially less in the latter trial.
We have developed an approach for assessing the risk of
developing CR! in patients with IMGN. This approach is based
on laboratory parameters well-known to be associated with an
adverse renal outcome [1—3], and can be used repetitively in
response to the patient's changing status. By quantifying this
risk, the clinician can establish a "threshold" to select patients
for a given treatment. This threshold may vary between clini-
cians depending on their assessment of the risks as well as the
effectiveness of the treatment. Using these strategies, one can
optimize the exposure of potentially toxic treatments to those
patients who would be most likely to benefit from them, at the
level of the individual patient or in the setting of a clinical trial.
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Appendix 1. Terms used to define a diagnostic test
Positive predictive value (PPV): Probability of having a disease in a
patient with a positive test result.
Negative predictive value (NPV): Probability of not having disease in
a patient with a negative test result.
Sensitivity (SEN): Probability of having a positive test result in a
person with a disease (that is, 'true-positive rate").
Specificity (SPEC): Probability of not having a positive test result in
a patient without disease (that is, "true-negative rate").
Accuracy: The proportion of all the results of a test condition, both
positive and negative, which correctly predicts the disease status.
Appendix 2. Probability modeling in IMGN
!n an attempt to improve further our ability to predict CR!, we added
two other variables of renal functional assessment in our patients during
each of the 15 levels of PP. on every occasion where a patient fulfilled
a specific level of PP(X, Yj, the Ccr at the start of PP(X1, Y), and its
rate of change during the same time period (SLP), were calculated. !f a
patient did not satisfy PP(X1, Yj, then the Ccr and SLP were calculated
on the next lower level of proteinuria, P(X) where X was proteinuria 
3 g/day, 2 g/day or 1 glday in descending order, and stored for the
modeling at PP(X, Y). If a patient never had over I g/day of proteinuna
for six months or more, the C. at the time of biopsy and the SLP over
his/her entire course would be used. Whenever possible, each SLP
calculation was based on a minimum of four data points. Fifteen models
using the above database were developed, and a score, R(CRI), was
generated by each model to estimate the risk of developing CR1 for each
patient. The positive and negative predictive values, sensitivity, spec-
ificity and accuracy for the prediction of CR1 by different R(CRI)
cut-offs were then determined within each model.
The logistic equation for predictive model is as follows:
exp(Ko + K1 x PP + K2 x SLP + K3 X Cr)
R(CRI) =
I + exp(Ko + K1 x PP + K2 x SLP + K3 x Ccr)
where PP is PP(X g/day for months): Yes = 1, No = 0; C. is
creatinine clearance at the start of the period of PP selected in
ml/min/1.73 m2; and SLP is the rate of change of Ccr during PP in
mI/mm x (1.73 m2)' x (year).
The coefficients for the predictive models are shown below:
K0 K1 K2 K3
M( 4 g/day for  18 months): 2.8 1.8 —0.094 —0.062
M( 6 g/day for  9 months): 1.4 1.5 —0.060 —0.044
M( 8 glday for  6 months): 0.3 2.1 —0.040 —0.031
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